B
02315
Biocytogen Pharmaceuticals (Beij…
35.08
6.38+22.23%Closed12:08 12/24 HKT
OPEN/PREV CLOSE29.020/28.700
TODAY RANGE28.920-35.820
VOL14.30M
MARKET CAP15.68B
52 WEEK RANGE7.070-35.860
AVG VOL (3M)768.82K
% TURNOVER3.20%
TURNOVER482.41M
P/E (TTM)108.138
% RANGE24.04%
EPS(TTM)0.324
P/E(FORWARD)-143.653
P/B16.027
BVPS2.189
DIVIDEND--
P/S12.005
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP3.89B
SHARES OUTSTANDING446.90M
NEXT EARNINGS--
FREE FLOAT110.78M
LOT SIZE500
EX-DATE--
News
Press Releases
Financial Reports
Profile
Reuters·12/05 00:00
IDEAYA Biosciences Receives FDA IND Clearance for IDE034 Bispecific ADC
Reuters·12/04 23:59
IDEAYA and Biocytogen Receive FDA Clearance for IND Application of IDE034
Reuters·11/26 22:31
Biocytogen Pharmaceuticals Beijing Announces A Share IPO on STAR Market
Reuters·11/19 22:41
Biocytogen Pharmaceuticals Announces Shanghai STAR Market IPO
Reuters·11/19 22:35
Biocytogen Pharmaceuticals Announces A Share IPO in Mainland China
Simply Wall St·11/13 22:34
Improved Revenues Required Before Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315) Stock's 43% Jump Looks Justified
Simply Wall St·10/28 00:40
Institutional investors control 30% of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315) and were rewarded last week after stock increased 7.0%
Simply Wall St·09/25 22:13
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315) Stock Catapults 32% Though Its Price And Business Still Lag The Industry
Simply Wall St·09/01 01:21
Biocytogen Pharmaceuticals (Beijing) First Half 2025 Earnings: EPS: CN¥0.12 (vs CN¥0.13 loss in 1H 2024)
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number : +852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email : service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation : marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.